A Phase II Single-arm Clinical Trial of Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer is a PHASE2 clinical asset sponsored by The First Affiliated Hospital with Nanjing Medical University in Breast Cancer. SEO and diligence focus: Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.